FonesLife

What FonesLife does

FonesLife Corporation is a Tokyo-based preventive healthcare company and wholly-owned subsidiary of NEC Solution Innovators (part of the NEC Group), founded in April 2020. The company operates FonesVisuas, a consumer-facing disease risk prediction service that draws a small blood sample (~5cc), measures approximately 7,000 blood proteins using SomaLogic's (now Standard BioTools') SomaScan aptamer-based proteomics platform, and uses NEC Group's AI and big-data analytics to predict future onset risk for dementia (20-year / 5-year windows for those 65+), myocardial infarction and stroke (4-year), lung cancer (5-year), chronic kidney failure (4-year), and prostate cancer (5-year, men 45+), alongside six current body-state metrics (glucose tolerance, cardiorespiratory endurance, alcohol impact, liver fat, visceral fat, resting metabolism). Each annual subscription pairs the test with two 40-minute health-advisor consultations and a personalized lifestyle improvement program; the service is sold direct-to-consumer through FonesLife's Shopify marketplace, through a network of 200+ contracted medical institutions across all 47 Japanese prefectures, and through enterprise wellness contracts facilitated by NEC Solution Innovators. International distribution began in early 2026 via Royal Healthcare in Singapore and N Health (BDMS group) in Thailand, with Saudi Arabia listed as an additional operating geography.

The company's underlying technology stack rests on two proteomics assets: the SomaScan Assay (SOMAmer-modified aptamers quantifying ~7,000–11,000 proteins per sample with median CV <5% and a 10^10 dynamic range) and the KREX / i-Ome protein microarray for ~1,800-autoantibody profiling. FonesLife holds the exclusive Japan-market license to SomaScan from Standard BioTools and operates a domestic measurement laboratory in Shin-Kiba, Tokyo. The research-services arm supplies pharmaceutical companies and academic institutions for biomarker discovery, disease mechanism studies, and drug development support, supplemented by a joint research grant program with Standard BioTools and academic collaborations with Kumamoto University, Chiba Cancer Center, and Kyushu University Hospital's Efra Lab. The company has been recognized with the 2025 Good Design Award and as a 2026 WELLBEING AWARDS finalist.

FonesLife's business model combines (1) annual consumer subscriptions (Standard and Pair plans) priced on a self-pay, non-insurance-covered basis, (2) B2B2C sales through medical institutions, (3) B2B enterprise wellness contracts via NEC Solution Innovators, and (4) research/professional services for pharma and academia. Headcount sits in the 51–100 range. The company has not publicly disclosed revenue or external funding rounds; as a wholly-owned NEC subsidiary, capital and enterprise distribution are sourced internally rather than from venture markets. The head office is in Hatchobori, Chuo-ku, Tokyo, with a measurement laboratory in Shin-Kiba and an R&D partnership footprint at Kyushu University Hospital.

Name

FonesLife

Legal name

フォーネスライフ株式会社

Website

https://foneslife.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

FonesLife is a Tokyo-based, NEC Group-owned preventive healthcare company offering FonesVisuas, a subscription service that uses SomaScan proteomics and NEC AI to predict future disease risk from a single blood test, sold to individuals, 200+ Japanese medical institutions, corporate wellness programs, and select Southeast Asian channel partners.

Ownership category

akta.pro rank

Product category

Preventive Healthcare Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Blood protein analysis
• Disease risk prediction
• Proteomics services
• Preventive healthcare screening
• Biomarker discovery

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. FonesVisuas Consumer Testing Service: Annual subscription model providing blood protein testing (single test) plus two health consultations (40 min each) with health advisor. Individual and couple/partner plans available. Purchased through medical institutions or online marketplace.
2. SomaScan™ Assay Research Services: Protein measurement services for research institutions and pharmaceutical companies. Supports biomarker discovery, disease research, drug development. Measurement available domestically (Shin-Kiba lab) or internationally (SomaLogic).
3. Research Grant Programs: Joint research grant programs with Standard BioTools supporting Japanese researchers with SomaScan and KREX services. Awards 4 recipients (2 each for SomaScan 11K Assay and KREX microarray) with 40 samples each.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

FonesLife analyzes approximately 7,000 blood proteins from a single ~5cc blood draw using licensed SomaScan aptamer-based proteomics technology to predict future onset risk of five diseases (dementia, myocardial infarction/stroke, lung cancer, chronic kidney failure, prostate cancer) and assess six current body-state markers, complemented by health-advisor (保健師) consultations that propose personalized lifestyle improvement plans. The company also sells research-use SomaScan Assay and KREX Protein Microarray services to research institutions and pharmaceutical companies.

Product overview

FonesLife offers two main product lines: (1) FonesVisuas — a consumer-facing disease risk prediction service for individuals and corporate health management that uses the SomaScan platform to analyze approximately 7,000 blood proteins, predicting future disease risk (dementia, myocardial infarction, stroke, lung cancer, chronic kidney failure, prostate cancer) and current body condition, combined with health consultant lifestyle recommendations; and (2) Research proteomics services including SomaScan™ Assay (measuring up to ~11,000 proteins for biomarker discovery and drug development) and KREX™ Protein Microarray (profiling ~1,800 autoantibodies). Both lines leverage SomaLogic/Standard BioTools' aptamer technology powered by NEC Group's big data analytics and ICT. The company targets individual consumers, medical institutions, and enterprise clients (via NEC Solution Innovators).

Differentiator

Problem solved

Functional benefit

Products and services

• FonesVisuas (フォーネスビジュアス) A consumer and enterprise preventive-healthcare service that measures approximately 7,000 blood proteins from a single ~5cc blood draw using SomaScan aptamer-based proteomics to predict 4–20 year onset risk of five diseases (dementia, myocardial infarction/stroke, lung cancer, chronic kidney failure, prostate cancer) and assess six current body-state markers (glucose tolerance, liver fat, alcohol impact, cardiorespiratory endurance, visceral fat, resting metabolism), with two 40-minute health-advisor (保健師) consultations that propose personalized lifestyle improvement plans. Sold as annual Standard and Pair subscriptions via the FonesLife Online Marketplace, contracted medical institutions (200+ across 47 prefectures), or NEC Solution Innovators for enterprise wellness programs.
• SomaScan Assay (Research Service) A research-use-only proteomics service that simultaneously measures up to approximately 11,000 proteins in blood or other biological samples using SOMAmer aptamer microarray technology, supporting biomarker discovery, disease mechanism research, drug development, and clinical trial subject stratification for academic researchers, pharmaceutical companies, and biotech firms. Available domestically through FonesLife's Shin-Kiba measurement laboratory in Tokyo or internationally via SomaLogic/Standard BioTools.
• KREX Protein Microarray (i-Ome Protein Array) A research service that comprehensively detects approximately 1,800 autoantibodies using full-length, correctly folded proteins on a proprietary microarray format, including i-Ome Discovery, i-Ome Cancer, Pan-Autoimmune, and OncoREX p53 panels. Used for cancer, autoimmune disease, and neurodegenerative disease research by academic and pharmaceutical clients.
• FonesVisuas Examination Gift Voucher A one-time gift voucher product for the FonesVisuas disease risk prediction examination, sold through the FonesLife Online Market and delivered by courier to a chosen recipient, designed as a present for special occasions.

Quantifiable outcome

• Covers approximately 10,000 unique human proteins (half the human proteome) from single blood sample
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered secondary and core.

• Royal Healthcare (Singapore)secondaryChannel Partner/ Reseller/ Distributor · 27 March 2026Singapore-based healthcare provider serving high-net-worth patients. First overseas adoption of FonesVisuas for luxury preventive healthcare services. Partnered through Sojitz Corporation group.
• Kyushu UniversitysecondaryStrategic or Co-development Partner · 26 January 2026FonesLife participates as a partner company at 'Efra Lab Kyushu University Hospital' - a life science incubation facility on the university hospital campus. Supports proteomics R&D collaboration and industry-academia partnerships.
• N Health (Thailand)coreChannel Partner/ Reseller/ Distributor · 15 January 2026Clinical testing company under BDMS (Bangkok Dusit Medical Services), Southeast Asia's largest healthcare group with 80+ facilities. Distributing FonesVisuas in Thailand through strategic partnership with NEC Thailand.
• NEC Corporation ThailandcoreStrategic or Co-development Partner · 15 January 2026NEC Thailand serves as the local implementation and go-to-market partner for FonesVisuas in Thailand, working with N Health and BDMS for market expansion.
• Standard BioToolscoreStrategic or Co-development Partner · 13 January 2026Joint research grant program 'Japan Proteomics Research Grant Award' supporting Japanese researchers. Standard BioTools provides SomaScan 11K Assay and KREX protein microarray services to award recipients.
• Chiba Cancer Center (千葉県がんセンター)secondaryStrategic or Co-development Partner · 30 September 2025Joint research collaboration validating the adaptation of prostate cancer risk prediction (newly added 5-year prostate cancer risk) for Japanese population.
• Kumamoto UniversitysecondaryStrategic or Co-development Partner · 12 September 2023Research collaboration on longitudinal evaluation of FonesVisuas examinees in Arao City, Kumamoto Prefecture. Kumamoto University Graduate School of Life Sciences conducts analysis and observational study evaluation.
• SomaLogic (now Standard BioTools)coreTechnology or Integration · 1 January 2020Exclusive licensing partnership for SomaScan Assay technology in Japan. SomaLogic developed the SOMAmer aptamer technology and SomaScan platform capable of measuring 7,000-11,000 proteins. FonesLife serves as the exclusive distributor and service provider in Japan.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Quest Diagnostics: One of the world's largest clinical laboratory services companies, offering routine and advanced specialty testing including proteomics to providers, employers, and consumers. Relevant broad incumbent comparison for the Japanese clinical-lab distribution model.
• Thorne HealthTech: US-listed personalized wellness company offering at-home biomarker tests, supplements, and AI-driven health insights, primarily through direct-to-consumer channels. Comparable business model combining consumer biomarker testing, recurring digital engagement, and premium pricing.
• Exact Sciences: US-listed diagnostics leader behind Cologuard and Oncotype DX, operating at the intersection of screening diagnostics and consumer health. Comparable business model logic (consumer-facing screening risk prediction), though at much larger scale.
• Natera: US-listed molecular diagnostics company with strong oncology, transplant, and women's health franchises; uses cfDNA/protein biomarker assays at scale. Comparable in high-multiplex biomarker testing and recurring revenue from clinical and research customers.
• Standard BioTools (formerly SomaLogic): Developer and licensor of the SomaScan aptamer-based proteomics platform that FonesLife exclusively distributes in Japan. Sells SomaScan assay services globally to pharma/research and is the upstream technology incumbent whose roadmap shapes FonesLife's offering.

Direct peers

• Fountain Life: US-based preventive health membership program that uses whole-body MRI, advanced blood biomarkers, and proteomics-based risk prediction. Direct competitor in the protein-driven disease risk prediction model targeting affluent consumers.
• Human Longevity Inc. Premium preventive health company combining whole-genome sequencing, advanced blood biomarkers, and AI-driven risk prediction. Closely comparable premium-risk-prediction service targeting health-conscious, high-income individuals.
• InsideTracker: Personalized health platform that integrates blood biomarker analysis with AI-driven recommendations and lifestyle coaching. Comparable in combining proteomics-style blood testing, AI analysis, and recurring consumer subscriptions.
• Genesis Healthcare Co., Ltd. Japan's leading direct-to-consumer genetic testing company offering disease risk and predisposition tests through medical institutions. Closest in-country competitor in the Japanese consumer predictive-diagnostics category.
• Prenetics (now Insighta): Hong Kong-listed preventive diagnostics company offering consumer genetic testing and early cancer screening across Asia. Most direct Asia-region comparison: similar preventive-screening positioning, consumer-direct revenue model, and cross-border healthcare ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/FonesLife
• YouTubeyoutube.com/channel/UCadbo-UJurenHdsMCj2vYFA
• Facebookfacebook.com/FonesLife%E3%83%95%E3%82%A9%E3%83%BC%E3%83%8D%E3%82%B9%E3%83%A9%E3%82%A4%E3%83%95-105978782047843

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FonesLife